Antitumor Drug Resistance

  • Brian W. Fox
  • Margaret Fox

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 72)

Table of contents

  1. Front Matter
    Pages I-XXV
  2. Concepts of Drug Resistance

    1. Front Matter
      Pages 1-1
    2. J. M. Whitehouse
      Pages 3-21
    3. J. F. Henderson
      Pages 23-36
  3. Modification of Host-Tumor Interaction

    1. Front Matter
      Pages 37-37
    2. J. G. McVie
      Pages 39-66
    3. H. Fuji
      Pages 67-87
  4. Cellular Aspects

    1. Front Matter
      Pages 99-99
    2. B. Drewinko, B. Barlogie
      Pages 101-141
    3. D. Scott
      Pages 205-239
    4. G. J. Goldenberg, A. Begleiter
      Pages 241-298
    5. J. M. Boyle
      Pages 299-332
  5. Modification of Tumor Biochemistry

    1. Front Matter
      Pages 333-333
    2. M. Fox
      Pages 335-369
    3. M. J. Tisdale
      Pages 371-389
    4. A. K. Belousova
      Pages 391-402
    5. K. D. Tew, P. S. Schein
      Pages 425-442
  6. Antimetabolites

    1. Front Matter
      Pages 443-443
    2. D. M. Tidd
      Pages 445-493
    3. A. D. Welch, N. K. Ahmed
      Pages 495-513
    4. J. A. Houghton, P. J. Houghton
      Pages 515-549
    5. J. R. Uren
      Pages 551-568
    6. W. T. Beck
      Pages 569-612
  7. Antifolates

    1. Front Matter
      Pages 613-613
    2. J. R. Bertino
      Pages 615-631
    3. M. M. IP
      Pages 633-669
  8. Modification of Resistance

    1. Front Matter
      Pages 671-671
  9. Back Matter
    Pages 699-740

About this book


The study of tumour resistance to anticancer drugs has been the subject of many publications since the initial discovery of the phenomenon by J. H. Burchenal and colleagues in 1950. Many papers have been published since then reporting development of resistance to most of the well-known anticancer agents in many different animal tumour systems, both in vivo and in vitro. Many different mechanisms of resistance have been described, and it is clear that the tumour cell has a wide diversity of options in overcoming the cell-killing activity of these agents. Definition of the magnitude of the phenomenon in the clinic is, however, much more problematical, and it is with this in mind that the initial chapter, seeks to out­ line the problem as the clinicians see it. It appears that the phenomenon of true resistance to a drug, as the biochemist would recognise it, is an important cause of the failure which clinicians experience in treating the disease. The extent of the contribution of this phenomenon to the failure of treatment cannot easily be evaluated at the present time, but it is hoped that the development and application of new and more sophisticated techniques for the analysis of cellular sub­ populations may help to give a more exact estimate and to shed some light on the causes of failure of many of the present therapeutic techniques.


Arzneimittelresistenz Zytostatikum cancer cell drug drug resistance resistance tumor

Editors and affiliations

  • Brian W. Fox
    • 1
  • Margaret Fox
    • 1
  1. 1.Paterson LaboratoriesChristie Hospital and Holt Radium InstituteWithington, ManchesterUK

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1984
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-69492-9
  • Online ISBN 978-3-642-69490-5
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods